US EditionPublished • loading... • Updated
Boehringer Ingelheim Plans for Dealmaking, Obesity Pipeline and R&D to Counter US Price Pressure
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Boehringer Ingelheim plans for dealmaking, obesity pipeline and R&D to counter US price pressure
Boehringer Ingelheim said it plans to keep up high levels of R&D spending, and could look at China-based companies for dealmaking, as key planks of its strategic approach this year, board chairman Shashank Deshpande said ...
Ingelheim – The pharmaceutical company Boehringer Ingelheim generated higher revenues from its human and animal medications in 2025. Two new drugs were launched: one for lung cancer in the US and one for pulmonary fibrosis in the US and China, the company announced. According to the company, the revenues...
The pharmaceutical company Boehringer Ingelheim increased its sales significantly last year. Now the German company wants to invest more in the USA.
·Düsseldorf, Germany
Read Full ArticleCoverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
